Cargando…

Expert consensus on management of metabolic disease in Chinese liver transplant recipients

Metabolic disease, including diabetes mellitus, hypertension, dyslipidemia, obesity, and hyperuricemia, is a common complication after liver transplantation and a risk factor for cardiovascular disease and death. The development of metabolic disease is closely related to the side effects of immunosu...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Tian, Zhuang, Li, Sun, Xiao-Dong, Qi, Xiao-Sheng, Wang, Zhi-Hui, Li, Rui-Dong, Chang, Wen-Xiu, Yang, Jia-Yin, Yang, Yang, Zheng, Shu-Sen, Xu, Xiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385566/
https://www.ncbi.nlm.nih.gov/pubmed/32774062
http://dx.doi.org/10.3748/wjg.v26.i27.3851
Descripción
Sumario:Metabolic disease, including diabetes mellitus, hypertension, dyslipidemia, obesity, and hyperuricemia, is a common complication after liver transplantation and a risk factor for cardiovascular disease and death. The development of metabolic disease is closely related to the side effects of immunosuppressants. Therefore, optimization of the immunosuppressive regimen is very important for the prevention and treatment of metabolic disease. The Chinese Society of Organ Transplantation has developed an expert consensus on the management of metabolic diseases in Chinese liver transplant recipients based on recent studies. Emphasis is placed on the risk factors of metabolic diseases, the effect of immunosuppressants on metabolic disease, and the prevention and treatment of metabolic diseases.